Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Active not recruiting 5Recruiting 4Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Specimen Handling 302Magnetic Resonance Spectroscopy 261pembrolizumab 249Carboplatin 184Cyclophosphamide 175Biopsy 167Cisplatin 157Gemcitabine 134Paclitaxel 130Bevacizumab 123fludarabine 115Nivolumab 108Radiotherapy 107Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 78Dexamethasone 76Pemetrexed 72Rituximab 69Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 64Doxorubicin 63Standard of Care 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × elotuzumab × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06208150 2026-06-05

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

Hoffmann-La Roche

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡